Ultragenyx Pharmaceutical Inc.

US$15.43As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RAREHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (12.53%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.36
PE TTM —
TSR TTM (55.40%)
Mkt cap US$1.568B
ROIC (32.20%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$18
19.31%
(56.51%)
Hold 6|1|12|3|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.26
0.25
0.28
0.27
30.91%
15.36%
19.16%
11.78%
Revenue$M
74.55
76.40
75.49
79.69
8.64%
14.58%
7.91%
9.49%
Peers (US$1.568B)
Cap (US$)
PE
1.603B
65.92x
Capital
TTM
5Y
10Y
Leveragex
0.072
(0.081)
(0.074)
EBIT/Intx
0.385
0.140
0.137
Own earn%
(33.03)
(12.73)
(26.33)
Sh yield%
14.82
4.14
8.04
Owners
Insiders/Inst%
7.76
60.10
Short interest%
5.81
SBC / revenue%
4.38
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
22–27
$1 testx
—
Incr. ROIC%
12